SAN FRANCISCO, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Excision BioTherapeutics, Inc., a clinical-stage biotechnology company developing CRISPR-based therapies to cure viral infectious diseases, today announced that interim clinical safety and biodistribution data will be presented at the 30th European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress, which will be held from October 24-27, 2023, in Brussels, Belgium.

旧金山，2023年10月19日（GLOBE NEWSWIRE）-Excision BioTherapeutics，Inc.，一家临床阶段生物技术公司，开发基于CRISPR的治疗病毒性传染病的疗法，今天宣布临床安全性和生物分布数据将在第30届欧洲基因和细胞治疗学会（ESGCT）2023年会，将于2023年10月24日至27日在比利时布鲁塞尔举行。

Dr. Rachel Presti of Washington University School of Medicine, a principal investigator for the clinical evaluation of EBT-101, will offer the first look at interim safety and biodistribution data from the EBT-101-001 Phase 1/2 clinical trial. EBT-101 is being evaluated in a first-in-human clinical study to assess its safety and efficacy in people with HIV on antiretroviral therapy.

华盛顿大学医学院的Rachel Presti博士是EBT-101临床评估的首席研究员，将首次关注EBT-101-001 1/2期临床试验的临时安全性和生物分布数据。EBT-101正在一项首次人体临床研究中进行评估，以评估其在HIV感染者抗逆转录病毒治疗中的安全性和有效性。

The presentation details are listed below, and the full program is available on the ESGCT website. Session: 5A Infectious Diseases & VaccinesDate/Time: Wednesday, October 25, 2023, 14:30-16:30 pm (CEST)Title: First-in-human trial of systemic CRISPR-Cas9 multiplex gene therapy for functional cure of HIV (OR31)Room: Shed 2A Parallel About EBT-101EBT-101 is a first-in-class in vivo CRISPR-based therapeutic designed to cure HIV infection after a single intravenous infusion.

演示文稿详细信息如下所示，完整程序可在ESGCT网站上找到。会议：5A传染病和疫苗接种日期/时间：2023年10月25日星期三，下午14:30-16:30（CEST）题目：用于功能性治愈的系统性CRISPR-Cas9多重基因治疗的首次人体试验HIV（OR31）室：与EBT-101EBT-101平行的2A脱落是一种一流的基于体内CRISPR的治疗剂，旨在在单次静脉输注后治愈HIV感染。

EBT-101 employs an adeno-associated virus (AAV) to deliver CRISPR-Cas9 and dual guide RNAs, enabling a multiplexed in vivo editing approach that simultaneously targets two distinct and conserved sites within the latent HIV genome distinct from the human genome. This allows for the excision of large portions of the HIV genome, thereby minimizing potential viral escape.

EBT-101采用腺相关病毒（AAV）传递CRISPR-Cas9和双引导RNA，实现多重体内编辑方法，同时靶向潜伏HIV基因组内与人类基因组不同的两个不同且保守的位点。这允许切除大部分HIV基因组，从而最小化潜在的病毒逃逸。

About the EBT-101 Clinical ProgramThe EBT-101-001 Phase 1/2 trial is an open-label, multi-center, single ascending dose study designed to .

关于EBT-101临床计划EBT-101-001 1/2期试验是一项开放标签，多中心，单次递增剂量研究。